Pfizer Q2 2024 Adj. EPS $0.60 Beats $0.46 Estimate, Sales $13.283B Beat $13.024B Estimate
Portfolio Pulse from Benzinga Newsdesk
Pfizer reported its Q2 2024 earnings, with adjusted EPS of $0.60 beating the estimate of $0.46, and sales of $13.283 billion surpassing the expected $13.024 billion.
July 30, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's Q2 2024 earnings report shows strong performance with adjusted EPS of $0.60 beating the $0.46 estimate, and sales of $13.283 billion exceeding the $13.024 billion estimate.
Pfizer's better-than-expected earnings and sales figures are likely to positively impact its stock price in the short term. The strong performance indicates robust business operations and financial health.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100